Lupin Limited has received a warning letter from the United States Food and Drug Administration (US FDA) for the company’s Tarapur, Maharashtra (India) facility after its inspection on March 22, 2022 to April 4, 2022.

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The company is committed to addressing the concerns raised by the US FDA and will work with the US FDA to resolve these issues at the earliest. The company upholds quality and compliance issues with utmost importance and remains committed to be compliant with CGMP quality standards across all our facilities.